title: Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
abstract: The purpose of the study is to test the hypothesis that expression of cell cycle regulatory proteins p16(INK4a) and pRb is significantly associated with prognosis in ovarian carcinomas. We performed immunohistochemical analysis of p16(INK4a) and pRb expression and correlated with survival in a series of 300 patients with FIGO stage IIb-IV ovarian carcinoma which were enrolled in a randomized prospective trial evaluating two different platinum and paxlitaxel chemotherapy combinations after radical surgery. p16(INK4a) negative tumours (17/300; 6%) had a significantly worse prognosis (univariate analysis, P<0.001; multivariate analysis: odds ratio 2.41, P=0.009). Among p16(INK4a)-positive tumours (283 out of 300; 94%), survival was better for patients with intermediate expression as compared to low or high expression levels (P=0.001). High expression levels of pRb were associated with an incremental deterioration of prognosis (univariate analysis, P=0.004; multivariate analysis: odds ratio 2.98, P=0.002). This observation held also true in the subgroup of optimally debulked patients (n=82), in whom the most important established prognostic factor, postoperative residual tumour cannot be applied. In conclusion p16(INK4a) and pRb are independent prognostic factors in advanced-stage ovarian carcinomas after radical surgery and postoperative chemotherapy. High pRb expression is a significant prognosticator in optimally debulked patients and may hold potential for subgroup stratification in postoperative treatment.
authors.affiliation: Dr-Horst-Schmidt-Klinik (HSK) Wiesbaden, Department of Gynecology & Gynecologic Oncology, Ludwig - Erhard - Str. 100, Wiesbaden 65199, Germany. stefan.kommoss@gyn-patho.de
authors.forename: S
authors.initials: S
authors.lastname: Kommoss
authors.forename: A
authors.initials: A
authors.lastname: du Bois
authors.forename: R
authors.initials: R
authors.lastname: Ridder
authors.forename: M J
authors.initials: MJ
authors.lastname: Trunk
authors.forename: D
authors.initials: D
authors.lastname: Schmidt
authors.forename: J
authors.initials: J
authors.lastname: Pfisterer
authors.forename: F
authors.initials: F
authors.lastname: Kommoss
mesh_terms: D003131:Combined Modality Therapy; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000502:physiology*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D011446:Prospective Studies; D016160:Retinoblastoma Protein / Q000502:physiology*; D015996:Survival Rate
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D016160:Retinoblastoma Protein